Form 8-K BIOGEN INC. For: Aug 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Biogen (BIIB) PT Raised to $292 at RBC Capital
August 2, 2024 6:24 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Biogen (NASDAQ: BIIB) to $292.00 (from $282.00) while maintaining a Outperform rating.
The analyst comments "BIIB's 2Q was better than today's stock action might suggest; while the beat was in partially driven by a few... More
Biogen (BIIB) tops Q2 expectations, raises profit guidance
August 1, 2024 7:27 AM EDTBiogen (NASDAQ: BIIB) reported its second-quarter results on Thursday, surpassing analyst expectations with an adjusted EPS of $5.28, significantly higher than the estimated $4.01.
The company's revenue also exceeded forecasts, coming in at $2.47 billion against a consensus estimate of $2.39 billion. Despite a flat year-over-year (YoY) total revenue, the adjusted EPS saw a notable 31% increase YoY.
The pharmaceutical giant's strong performance is reflected in its raised full-year... More
